Innocoll Hld Ord Shr (INNL) 6.20 $INNL Innocoll
Post# of 273323
Posted On: 09/22/2016 3:14:48 AM
Innocoll Hld Ord Shr (INNL) 6.20 $INNL
Innocoll Holdings plc to Present at the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Wed Sep 07, 3:01PM CDT
Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need, today announced that Anthony Zook, Chief Executive Officer of Innocoll Holdings plc, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016, at 11:10 a.m. ET at the Grand Hyatt Hotel in New York, NY.
INNL: 6.20 (+0.15), MS: 31.92 (+0.22)
Innocoll to Report Second Quarter 2016 Financial Results and Host Webcast and Conference Call on August 17, 2016
GlobeNewswire - Thu Aug 11, 3:01PM CDT
Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need, today announced that it will report second quarter financial results before the open of U.S. financial markets on August 17, 2016. Innocoll management will host a webcast and conference call at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
INNL: 6.20 (+0.15)
Innocoll Holdings plc Announces Closing of Public Offering
GlobeNewswire - Wed Jun 22, 3:30PM CDT
Innocoll Holdings plc (Nasdaq:INNL), a specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need, today announced the closing of its previously announced underwritten public offering of 5,725,000 ordinary shares at a public offering price of $7.00 per ordinary share. In addition, Innocoll has granted the underwriters of the offering a 30-day option to purchase up to an additional 858,750 ordinary shares in connection with the offering to cover over-allotments.
INNL: 6.20 (+0.15), MS: 31.92 (+0.22)
Innocoll Holdings plc to Present at the JMP Securities Life Sciences Conference
GlobeNewswire - Thu Jun 16, 8:20AM CDT
Innocoll Holdings plc (Nasdaq:INNL) a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need, today announced that Anthony Zook, Chief Executive Officer of Innocoll Holdings plc, will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 2:30 p.m. ET, at the St. Regis hotel in New York, NY.
INNL: 6.20 (+0.15)
Innocoll Holdings plc Announces First Quarter 2016 Financial and Operating Results and Provides Corporate Update
GlobeNewswire - Tue May 31, 3:04PM CDT
Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need, announced financial and operating results for the three months ended March 31, 2016. We manufacture and supply a range of pharmaceutical products and medical devices using our proprietary collagen-based biodegradable and fully bioresorbable technology platform.
INNL: 6.20 (+0.15)
Innocoll Stock Gains on Favorable Phase III Data on Xaracoll
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:21AM CDT
Shares of Innocoll (INNL) rallied after the company announced positive data from two phase III studies on Xaracoll for the treatment of postoperative pain relief.
INNL: 6.20 (+0.15), ANIP: 65.12 (+0.28), PFE: 34.28 (+0.47), BMY: 55.93 (+0.37)
Innocoll Announces XARACOLL(R) (bupivacaine-collagen bioresorbable implant) Meets Primary Endpoint in Both Pivotal Phase 3 Trials in Postoperative Pain Relief
GlobeNewswire - Wed May 25, 6:30AM CDT
-- First long-acting, opioid-sparing, local analgesic to meet primary endpoints of Phase 3 clinical trials in hernia repair
INNL: 6.20 (+0.15)
Innocoll to Host Live Webcast on Top-Line Results from Two Pivotal Phase 3 Trials of XARACOLL(R) (bupivacaine-collagen bioresorbable implant) in Postoperative Pain Relief
GlobeNewswire - Tue May 24, 3:15PM CDT
Innocoll (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company, today announced that the Company will host a live webcast and conference call to review top-line results of its two, identical Phase 3 studies of XaraColl(R) (bupivacaine-collagen bioresorbable implant) for the treatment of postoperative pain relief immediately following open abdominal hernia repair.
INNL: 6.20 (+0.15)
Innocoll to Report First Quarter 2016 Financial Results and Host Webcast and Conference Call on May 31, 2016
GlobeNewswire - Wed May 18, 3:10PM CDT
Innocoll Holdings plc (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that it will report first quarter financial results after the close of U.S. financial markets on May 31, 2016. Innocoll management will host a webcast and conference call at 4:30 p.m. EDT that day to discuss the financial results and provide a corporate update.
INNL: 6.20 (+0.15)
Innocoll Holdings plc Appoints Lesley Russell, MBChB, MRCP, as Chief Medical Officer
GlobeNewswire - Wed Apr 20, 3:43PM CDT
Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need, today announced that Lesley Russell, MBChB, MRCP, has been appointed chief medical officer. Dr. Russell will be responsible for managing all clinical development programs as well as medical and regulatory affairs for the company.
INNL: 6.20 (+0.15)
Innocoll AG Appoints Charles Katzer as Head of Manufacturing and Technical Operations
GlobeNewswire - Thu Dec 17, 7:30AM CST
Innocoll AG (NASDAQ:INNL) announced that Charles Katzer has been appointed head of Manufacturing and Technical Operations effective immediately. The addition of this role to the senior management team is part of its strategic plan to transition Innocoll into a commercial-stage, fully-integrated specialty pharmaceutical company.
INNL: 6.20 (+0.15)
Innocoll AG Announces Third Quarter 2015 Financial and Operating Results and Corporate Update
GlobeNewswire - Wed Nov 11, 7:00AM CST
Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced financial and operating results for the three and nine months ended September 30, 2015.
INNL: 6.20 (+0.15)
Innocoll AG Announces First Patient Dosed in the XaraColl MATRIX-2 Phase 3 Study for the Treatment of Postoperative Pain
GlobeNewswire - Wed Sep 16, 7:00AM CDT
Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that the first patient was dosed in the MATRIX-2 (Multisite Assessment of PosToperative Pain Reduction wIth XaraColl) Phase 3 study for the treatment of postoperative pain following open hernioplasty with mesh using XaraColl, Innocoll's surgically implantable and bioresorbable bupivacaine-collagen matrix.
INNL: 6.20 (+0.15)
Innocoll AG Announces Departure of Chief Medical Officer
GlobeNewswire - Mon Sep 14, 7:00AM CDT
Innocoll AG (NASDAQ:INNL) announced that James P. Tursi, M.D., will depart Innocoll to pursue another opportunity. Dr. Tursi will remain with Innocoll until September 21, 2015.
INNL: 6.20 (+0.15)
Innocoll AG Announces Second Quarter 2015 Financial and Operating Results and Updates Late-Stage Product Portfolio Progress
GlobeNewswire - Fri Aug 14, 7:00AM CDT
Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced financial and operating results for the three and six months ended June 30, 2015.
INNL: 6.20 (+0.15)
Innocoll AG Appoints Rich Fante as Chief Commercial Officer and Head of Business Development
GlobeNewswire - Thu Aug 13, 7:00AM CDT
Innocoll AG (NASDAQ:INNL) announced that Rich Fante has been appointed Chief Commercial Officer and Head of Business Development effective August 20, 2015. The addition of this role to the senior management team is an additional step in the transition of the company to a commercial-stage, fully-integrated specialty pharmaceutical company.
INNL: 6.20 (+0.15)
Innocoll to Report Second Quarter 2015 Financial Results and Host Webcast and Conference Call on August 14, 2015
GlobeNewswire - Fri Aug 07, 7:00AM CDT
Innocoll AG (Nasdaq:INNL) (the "Company"
, a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that it will report second quarter financial results before the open of U.S. financial markets on August 14, 2015. Innocoll management will host a webcast and conference call at 8:30 a.m. EDT that day to discuss the financial results and provide a corporate update.
INNL: 6.20 (+0.15)
Innocoll AG Appoints Jose Carmona as Chief Financial Officer
GlobeNewswire - Wed Jul 01, 6:00AM CDT
Appointment is effective on September 1, 2015
INNL: 6.20 (+0.15)
Innocoll AG Announces Qualified Infectious Disease Product (QIDP) Designation for Cogenzia for the Adjunctive Treatment of Moderate and Severe Diabetic Foot Infection
GlobeNewswire - Tue Jun 30, 6:00AM CDT
Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that the Cogenzia gentamicin collagen matrix has received Qualified Infectious Disease Product (QIDP) designation for the adjunctive treatment of moderate and severe diabetic foot infection from the FDA.
INNL: 6.20 (+0.15)
Innocoll Holdings plc to Present at the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Wed Sep 07, 3:01PM CDT
Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need, today announced that Anthony Zook, Chief Executive Officer of Innocoll Holdings plc, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016, at 11:10 a.m. ET at the Grand Hyatt Hotel in New York, NY.
INNL: 6.20 (+0.15), MS: 31.92 (+0.22)
Innocoll to Report Second Quarter 2016 Financial Results and Host Webcast and Conference Call on August 17, 2016
GlobeNewswire - Thu Aug 11, 3:01PM CDT
Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need, today announced that it will report second quarter financial results before the open of U.S. financial markets on August 17, 2016. Innocoll management will host a webcast and conference call at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
INNL: 6.20 (+0.15)
Innocoll Holdings plc Announces Closing of Public Offering
GlobeNewswire - Wed Jun 22, 3:30PM CDT
Innocoll Holdings plc (Nasdaq:INNL), a specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need, today announced the closing of its previously announced underwritten public offering of 5,725,000 ordinary shares at a public offering price of $7.00 per ordinary share. In addition, Innocoll has granted the underwriters of the offering a 30-day option to purchase up to an additional 858,750 ordinary shares in connection with the offering to cover over-allotments.
INNL: 6.20 (+0.15), MS: 31.92 (+0.22)
Innocoll Holdings plc to Present at the JMP Securities Life Sciences Conference
GlobeNewswire - Thu Jun 16, 8:20AM CDT
Innocoll Holdings plc (Nasdaq:INNL) a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need, today announced that Anthony Zook, Chief Executive Officer of Innocoll Holdings plc, will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 2:30 p.m. ET, at the St. Regis hotel in New York, NY.
INNL: 6.20 (+0.15)
Innocoll Holdings plc Announces First Quarter 2016 Financial and Operating Results and Provides Corporate Update
GlobeNewswire - Tue May 31, 3:04PM CDT
Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need, announced financial and operating results for the three months ended March 31, 2016. We manufacture and supply a range of pharmaceutical products and medical devices using our proprietary collagen-based biodegradable and fully bioresorbable technology platform.
INNL: 6.20 (+0.15)
Innocoll Stock Gains on Favorable Phase III Data on Xaracoll
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:21AM CDT
Shares of Innocoll (INNL) rallied after the company announced positive data from two phase III studies on Xaracoll for the treatment of postoperative pain relief.
INNL: 6.20 (+0.15), ANIP: 65.12 (+0.28), PFE: 34.28 (+0.47), BMY: 55.93 (+0.37)
Innocoll Announces XARACOLL(R) (bupivacaine-collagen bioresorbable implant) Meets Primary Endpoint in Both Pivotal Phase 3 Trials in Postoperative Pain Relief
GlobeNewswire - Wed May 25, 6:30AM CDT
-- First long-acting, opioid-sparing, local analgesic to meet primary endpoints of Phase 3 clinical trials in hernia repair
INNL: 6.20 (+0.15)
Innocoll to Host Live Webcast on Top-Line Results from Two Pivotal Phase 3 Trials of XARACOLL(R) (bupivacaine-collagen bioresorbable implant) in Postoperative Pain Relief
GlobeNewswire - Tue May 24, 3:15PM CDT
Innocoll (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company, today announced that the Company will host a live webcast and conference call to review top-line results of its two, identical Phase 3 studies of XaraColl(R) (bupivacaine-collagen bioresorbable implant) for the treatment of postoperative pain relief immediately following open abdominal hernia repair.
INNL: 6.20 (+0.15)
Innocoll to Report First Quarter 2016 Financial Results and Host Webcast and Conference Call on May 31, 2016
GlobeNewswire - Wed May 18, 3:10PM CDT
Innocoll Holdings plc (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that it will report first quarter financial results after the close of U.S. financial markets on May 31, 2016. Innocoll management will host a webcast and conference call at 4:30 p.m. EDT that day to discuss the financial results and provide a corporate update.
INNL: 6.20 (+0.15)
Innocoll Holdings plc Appoints Lesley Russell, MBChB, MRCP, as Chief Medical Officer
GlobeNewswire - Wed Apr 20, 3:43PM CDT
Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need, today announced that Lesley Russell, MBChB, MRCP, has been appointed chief medical officer. Dr. Russell will be responsible for managing all clinical development programs as well as medical and regulatory affairs for the company.
INNL: 6.20 (+0.15)
Innocoll AG Appoints Charles Katzer as Head of Manufacturing and Technical Operations
GlobeNewswire - Thu Dec 17, 7:30AM CST
Innocoll AG (NASDAQ:INNL) announced that Charles Katzer has been appointed head of Manufacturing and Technical Operations effective immediately. The addition of this role to the senior management team is part of its strategic plan to transition Innocoll into a commercial-stage, fully-integrated specialty pharmaceutical company.
INNL: 6.20 (+0.15)
Innocoll AG Announces Third Quarter 2015 Financial and Operating Results and Corporate Update
GlobeNewswire - Wed Nov 11, 7:00AM CST
Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced financial and operating results for the three and nine months ended September 30, 2015.
INNL: 6.20 (+0.15)
Innocoll AG Announces First Patient Dosed in the XaraColl MATRIX-2 Phase 3 Study for the Treatment of Postoperative Pain
GlobeNewswire - Wed Sep 16, 7:00AM CDT
Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that the first patient was dosed in the MATRIX-2 (Multisite Assessment of PosToperative Pain Reduction wIth XaraColl) Phase 3 study for the treatment of postoperative pain following open hernioplasty with mesh using XaraColl, Innocoll's surgically implantable and bioresorbable bupivacaine-collagen matrix.
INNL: 6.20 (+0.15)
Innocoll AG Announces Departure of Chief Medical Officer
GlobeNewswire - Mon Sep 14, 7:00AM CDT
Innocoll AG (NASDAQ:INNL) announced that James P. Tursi, M.D., will depart Innocoll to pursue another opportunity. Dr. Tursi will remain with Innocoll until September 21, 2015.
INNL: 6.20 (+0.15)
Innocoll AG Announces Second Quarter 2015 Financial and Operating Results and Updates Late-Stage Product Portfolio Progress
GlobeNewswire - Fri Aug 14, 7:00AM CDT
Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced financial and operating results for the three and six months ended June 30, 2015.
INNL: 6.20 (+0.15)
Innocoll AG Appoints Rich Fante as Chief Commercial Officer and Head of Business Development
GlobeNewswire - Thu Aug 13, 7:00AM CDT
Innocoll AG (NASDAQ:INNL) announced that Rich Fante has been appointed Chief Commercial Officer and Head of Business Development effective August 20, 2015. The addition of this role to the senior management team is an additional step in the transition of the company to a commercial-stage, fully-integrated specialty pharmaceutical company.
INNL: 6.20 (+0.15)
Innocoll to Report Second Quarter 2015 Financial Results and Host Webcast and Conference Call on August 14, 2015
GlobeNewswire - Fri Aug 07, 7:00AM CDT
Innocoll AG (Nasdaq:INNL) (the "Company"
, a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that it will report second quarter financial results before the open of U.S. financial markets on August 14, 2015. Innocoll management will host a webcast and conference call at 8:30 a.m. EDT that day to discuss the financial results and provide a corporate update. INNL: 6.20 (+0.15)
Innocoll AG Appoints Jose Carmona as Chief Financial Officer
GlobeNewswire - Wed Jul 01, 6:00AM CDT
Appointment is effective on September 1, 2015
INNL: 6.20 (+0.15)
Innocoll AG Announces Qualified Infectious Disease Product (QIDP) Designation for Cogenzia for the Adjunctive Treatment of Moderate and Severe Diabetic Foot Infection
GlobeNewswire - Tue Jun 30, 6:00AM CDT
Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that the Cogenzia gentamicin collagen matrix has received Qualified Infectious Disease Product (QIDP) designation for the adjunctive treatment of moderate and severe diabetic foot infection from the FDA.
INNL: 6.20 (+0.15)
(0)
(0)